

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Memorial Sloan Kettering Cancer Center & Treatment](#)

[About Cancer & Treatment](#)

What can we help you find today?

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Samuel Singer, MD, FACS

Surgeon ([#about-me](#))



Areas of Expertise

Conditions I Treat

- Soft tissue sarcomas
- Malignant peripheral nerve sheath tumor (MPNST)
- Desmoid tumor (benign)

My Specialties

- Targeted therapy



[Dr. Singer's Office Information \(#contact-and-location\)](#)



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9072](#)

[Make an appointment](#)

Get to Know Me

I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors.

Read more +

What I Do at MSK

I'm a surgeon, which is a doctor with special training in many types of surgery.

- Chief, Gastric and Mixed Tumor Service
- Vincent Astor Chair of Clinical Research

Areas of Expertise

Conditions I Treat

- Soft tissue sarcomas
- Malignant peripheral nerve sheath tumor (MPNST)
- Desmoid tumor (benign)

My Specialties

- Targeted therapy

Education & Honors

Education

- MD, Harvard University

Residencies

- General Surgery - Brigham and Women's Hospital

Fellowships

- Oncology - Francis Bitter National Magnet Laboratory

Board Certifications

- Surgery

Awards and Honors

- Castle Connolly: America's Top Doctor (2026)
- Castle Connolly: America's Top Doctor (2025)
- Castle Connolly: America's Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2003-2010, 2019-2020)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [646-497-9072](tel:646-497-9072) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location


Office Phone

 [212-639-2940](tel:212-639-2940)

Location

 New York, NY

[Rockefeller Outpatient Pavilion](#)

 160 East 53rd Street
New York, NY 10022
[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Gastric and Mixed Tumor Service doctors](https://www.mskcc.org/doctor?field_vocab_departments%5B872%5D=872) (https://www.mskcc.org/doctor?field_vocab_departments%5B872%5D=872)

[See all Surgery doctors](https://www.mskcc.org/doctor?field_vocab_departments%5B868%5D=868) (https://www.mskcc.org/doctor?field_vocab_departments%5B868%5D=868)

Clinical Trials





Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials \(https://www.mskcc.org/cancer-care/clinical-trials\)](https://www.mskcc.org/cancer-care/clinical-trials)

Research and Publications

[View Dr. Singer's Lab](#)

[Cancer Genome Atlas Network. Comprehensive and integrated characterization of adult soft tissue sarcomas. *Cell* 2017; 171\(4\): 950-965.](#)

[Mazzu YZ, Hu Y, Soni RK, Mojica KM, Qin LX, Agius P, Waxman ZM, Mihailovic A, Socci ND, Hendrickson RC, Tuschl T, Singer S. 2017. miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. *Cancer Res* 2017; 77: 5728-40.](#)

[Okada T, Lee AY, Qin LX, Agaram N, Mimae T, Shen Y, O'Connor R, Lopez-Lago MA, Craig A, Miller ML, Agius P, Molinelli E, Socci ND, Crago AM, Shima F, Sander C, Singer S. Integrin-alpha10 dependency identifies RAC and RICTOR as therapeutic targets in high-grade myxofibrosarcoma. *Cancer Discov* 2016; 6\(10\): 1148-1165.](#)

[Lee AY, Agaram NP, Qin LX, Kuk D, Curtin C, Brennan MF, Singer S. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. *Ann Surg Oncol* 2016; 23\(3\):818-25.](#)

[Tan MC, Brennan MF, Kuk D, Agaram NP, Antonescu CR, Qin LX, Moraco N, Crago AM, Singer S. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. *Ann Surg* 2016;263\(3\):593-600.](#)

[Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000](#)

[patients with soft tissue sarcoma. *Ann Surg* 2014; 260:416-422.](#)

Publications on PubMed

Visit PubMed for a full listing of Dr. Singer's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%22sarcoma%22%5BMH%5D%29%20OR%20sloan-kettering%20AND%20Singer%20S%5BAU%5D%20NOT%20Singer%20SJ%5BAU%5D%29\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%22sarcoma%22%5BMH%5D%29%20OR%20sloan-kettering%20AND%20Singer%20S%5BAU%5D%20NOT%20Singer%20SJ%5BAU%5D%29)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Samuel Singer discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center